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Purpose: This study aimed to evaluate the pathological characteristics, immunophenotype,
and prognosis of treatment-emergent neuroendocrine prostate cancer (T-NEPC).
Materials and Methods: We collected 231 repeated biopsy specimens of castrationresistant prostate cancer (CRPC) cases between 2008 and 2019. We used
histopathological and immunohistochemical evaluations of Synaptophysin (SYN),
ChromograninA (CgA), CD56, androgen receptor (AR), and prostate-speciﬁc antigen
(PSA) to screen out T-NEPC cases. Multivariate analyses were performed to identify
factors in the prognosis of T-NEPC. Further, the results were veriﬁed in the Surveillance,
Epidemiology, and End Results (SEER) program.
Results: Among the 231 CRPC cases, 94 (40.7%) cases were T-NEPC. T-NEPC were
more likely to present with negative immunohistochemistry for AR (30.9%) and PSA
(47.9%) than that of CRPC (8.8% and 17.5%, respectively). Kaplan-Meier analysis
revealed that patients with T-NEPC (median overall survival [OS]: 17.6 months, 95% CI:
15.3–19.9 months) had signiﬁcantly worse survival compared with usual CRPC patients
(median OS: 23.6 months, 95% CI: 21.3-25.9 months, log-rank P = 0.001), especially in
metastasis cases (median OS: 15.7 months, 95% CI: 13.3-18.0 months) and patients with
small cell carcinoma component (median OS: 9.7 months, 95% CI: 8.2–11.2 months).
Prostate adenocarcinoma with diffuse NE differentiation (median OS: 18.8 months, 95%
CI: 15.3–22.3 months) had poor outcome than those with usual CRPC (P = 0.027), while
there was no signiﬁcant change in the focal NE differentiation (median OS: 22.9 months,
95% CI: 18.1–27.7 months, P = 0.136). In the unadjusted model, an excess risk of overall
death was observed in T-NEPC with PSA negative (HR = 2.86, 95% CI = 1.39–6.73).
Among 476 NEPC cases in the SEER database from 2004 to 2017, we observed a higher
hazard of overall death in patients aged 65 years and older (HR = 1.35, 95% CI = 1.08–
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1.69), patients with PSA ≤ 2.5 ng/ml (HR = 1.90, 95%CI = 1.44–2.52), patients with PSA
2.6–4.0 ng/ml (HR = 2.03, 95%CI = 1.38–2.99), stage IV tumor (HR = 2.13, 95%CI =
1.47–3.08) and other races (HR = 1.85, 95%CI = 1.17–2.94) in total NEPC, adjusting for
confounders. Similar hazard ratios were observed in pure NEPC, while there was no
signiﬁcant results among prostate adenocarcinoma with NE differentiation tumors.
Conclusion: T-NEPC was associated with an unfavorable prognosis, negative
immunohistochemistry for PSA in T-NEPC and serum PSA level ≤ 4 ng/ml had a worse
prognosis. Urologists and pathologists should recognize the importance of the second
biopsy in CRPC to avoid unnecessary diagnosis and treatment delays.
Keywords: treatment-emergent neuroendocrine prostate cancer, castration-resistant prostate cancer, small cell
carcinoma, immunohistochemistry, SEER program

Northern Theater Command, and the Liaoning Cancer
Hospital & Institute of China Medical University between 2008
and 2019. Overall survival (OS) was deﬁned as the time interval
between the date of CRPC or T-NEPC diagnosis and the date of
death or last follow-up. By the Declaration of Helsinki, written
informed consent was obtained from all participants. This study
w a s a p p r o v e d b y th e E t h i c s C om m i t t e e o f C h i n a
Medical University.

INTRODUCTION
Treatment-emergent neuroendocrine prostate cancer (T-NEPC)
mainly occurs in the advanced castration-resistant prostate cancer
(CRPC), which is caused by the transformation of ordinary prostate
adenocarcinoma after androgen-deprivation therapy (ADT) (1). The
main clinical manifestations of T-NEPC include low PSA level, high
tumor metastasis load, and rapid resistance to ADT (2). T-NEPC is
an aggressive variant of CRPC, with a poor prognosis. Most T-NEPC
patients die within 1 to 2 years after diagnosis, accounting for
approximately 25% of CRPC deaths (3). The clinical acquaintance
of conversion to T-NEPC after resistance to endocrine therapy in
prostate adenocarcinoma is insufﬁcient, and secondary biopsies are
not routinely performed, cause to the missed diagnosis of T-NEPC.
At present, there is still no pathological consensus deﬁnition of TNEPC. The morphological characteristics of T-NEPC are similar to
poorly differentiated prostate adenocarcinoma, so the incidence of TNEPC is greatly underestimated (4). In recent years, with the
widespread use of novel, highly potent androgen receptor-targeted
therapies (eg, Arbiton, MDV3100), the incidence of T-NEPC may
also rise signiﬁcantly. T-NEPC is not sensitive to ADT treatment,
and the treatment is different from adenocarcinoma. Once T-NEPC
is diagnosed, systemic chemotherapy based on etoposide combined
with cisplatin (EP) or carboplatin(CE) should be performed as soon
as possible, as well as radiotherapy, and other potentially effective
treatment includes targeted drugs such as Aurora kinase A
(AURKA) kinase inhibitors, anti-EGFR and mTOR inhibitors (5,
6) if necessary. Therefore, early diagnosis and treatment are of great
signiﬁcance to improve the patient’s survival beneﬁt. But there are
very few clinical series studies to date, and the clinical characteristics
and prognosis of T-NEPC are not very clear. Therefore, we analyzed
the clinicopathologic characteristics and outcomes of T-NEPC,
intending to improve the understanding of T-NEPC among
clinicians and pathologists.

Immunohistochemistry
All the specimens had been ﬁxed by 10% formalin and parafﬁnembedded routinely. Four µm thickness tissue sections from
blocks were stained with hematoxylin and eosin (H&E) and
immunohistochemical staining (Syn, CgA, CD56, AR, and PSA).
Immunohistochemistry was performed by the avidin-biotinperoxidase complex method (MaiXin Inc, China, prediluted)
according to the manufacturer’s instruction.

Immunohistochemical Evaluation
Two independent, blinded investigators, XSQ and QFZ evaluated
all the slides. AR immunopositivity was located in the nucleus,
CD56 immunopositivity was located in both the cell membrane
and cytoplasm, PSA, SYN, and CgA immunopositivity
were located in the cytoplasm. At least 10% of tumor cells
showed at least one NE marker positive was considered as NE
differentiation. According to the staining intensity, the
expression level of immunohistochemical staining was scored
as: 0 point (negative), 1 point (weak expression), 2 points
(moderate expression-strong expression); staining cell
percentage evaluation score: 0 point (0%–10%), 1 point (10%–
50%), 2 points (51%–100%). The scores of staining intensity and
the percentage of staining cells were multiplied, and the ﬁnal
score was >1 point was positive.

SEER Cohort
We used the SEER database (released in April of 2020) to identify
eligible NEPC cases. This study included men diagnosed with
malignant prostate adenocarcinomas between 2004 and 2017 (n
= 780,379) because the SEER database did not collect PSA
information until 2004. We excluded non-microscopically
conﬁrmed cases, patients with a prior cancer history, unknown

MATERIALS AND METHODS
Case Selection
A total of 231 cases of CRPC were collected from the First Afﬁliated
Hospital of China Medical University, General Hospital of
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survival time, men without PSA level. The ﬁnal analytic sample
included 476 NEPC cases (Figure 1). Due to the use of deidentiﬁed data, this study was determined as exempt by the
Institutional Review Board of the First Hospital of China
Medical University.

which 31 cases (54.4%) were bone metastasis, 13 (22.8%) cases
were lymph nodes metastasis and 22 (38.6%) cases present organ
(Brain, Lung, Liver. etc) metastasis, 12 (21.1%) cases were
multiple metastases. 190 (82.3%) cases were AR positive, all
were moderate-strong positive, 162 (70.1%) cases were PSA
positive, of which 26 cases were weak positive. Among TNEPC cases, 54 (57.4%) cases were CgA positive, 79 (84.0%)
cases were SYN positive, 39 (41.5%) cases were CD56 positive. 31
(33.0%) cases were positive for only 1 neuroendocrine marker, 41
(43.6%) were positive 2 neuroendocrine markers, and 22 cases
(23.4%) were positive for both 3 neuroendocrine markers.

Statistical Analysis
Chi-squared tests were applied to analyze the clinicopathological
characteristics of subgroups. Survival curves were plotted
according to the Kaplan-Meier method and compared using the
log-rank test in a univariate analysis. Multivariate analysis was
performed using the Cox proportional hazards model. The
estimated risks for overall survival (OS) were calculated as
hazard ratios (HRs) with 95% conﬁdence intervals (CIs). All
statistical analyses were performed using SAS (version 9.4; SAS
Institute, Cary, NC) or SPSS 22.0. Statistical signiﬁcance was
assessed as two-sided P<0.05.

Histological Findings
The cases were divided into ﬁve groups according to morphological
and the expression extent of neuroendocrine markers: 1. Usual
CRPC, there were 137 cases, of which 125 cases were AR positive
and 113 cases were PSA positive. 2. Prostate adenocarcinoma with
focal increased neuroendocrine differentiation (Figures 2A–F),
conﬁrmed by immunohistochemistry with neuroendocrine
differentiation, but did not meet the criteria of group 3, of which
23 cases were matched, all 23 cases were AR positive, and 17 cases
were PSA positive. And there were 16 cases with Gleason score >7, 7
cases with Gleason score ≤7. 3. Prostate adenocarcinoma with
diffuse neuroendocrine differentiation (typical prostate acinar
adenocarcinoma or prostate ductal adenocarcinoma with at least
1 neuroendocrine marker >50% positive) (Figures 2G–R), and of
which 34 cases were matched, 27 cases were AR positive, and 23
cases were PSA positive. In addition, there were 30 cases with
Gleason score > 7, 4 cases with Gleason score ≤ 7. 4. Highly

RESULTS
Clinicopathological Features
Of the 231 cases, ages ranged from 51 to 82 years (mean, 68.5
years). The tumor size ranged from 1.5 to 8 cm (mean, 2.6 cm).
40.7% (n = 94) cases were T-NEPC. The median time from the
initial diagnosis of prostate adenocarcinoma to the diagnosis of
T-NEPC was 24.3 months (19.4–62.8 months). After T-NEPC
diagnosis, 53 (56.4%) cases were treated with radiotherapy or
chemotherapy. 57 (60.6%) cases appeared metastasis, among

FIGURE 1 | Flowchart of eligible individuals, surveillance, epidemiology, and end results (SEER) 18 registries, 2004–2017.
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FIGURE 2 | The histomorphology and immunohistochemistry of prostate adenocarcinoma with focal/diffuse increased neuroendocrine differentiation. (A) Prostate
adenocarcinoma with focal increased neuroendocrine differentiation, the tumor cells show androgen receptor (AR) (B) and prostate-speciﬁc antigen (PSA) (C)
positive, and focal express CD56 (D), Syn (E), and CgA (F); (G) prostate adenocarcinoma with diffuse neuroendocrine differentiation, the tumor cells show AR (H)
and PSA (I) positive, and negative express CD56 (J), but Syn (K), and CgA (L) diffuse positive; (M) prostate adenocarcinoma with diffuse neuroendocrine
differentiation, the tumor cells show AR (N) and PSA (O) negative, and diffuse express CD56 (P), Syn (Q) and CgA (R).

differentiated neuroendocrine cancer (Figures 3A–F): it was
characterized by the nest-like structure and uniform nucleus, and
the cytoplasm was peppered with salt-like chromatin or eosinophilic
granules. And immunohistochemistry showed neuroendocrine
differentiation. Only two cases were matched, and both AR and
PSA staining were negative. 5. Poorly differentiated neuroendocrine
carcinoma: 35 cases were matched, 15 cases were AR positive, and
nine cases were PSA positive. And among them, two cases were
large-cell neuroendocrine carcinoma (Figures 3G–L), 22 cases were
small-cell carcinoma (Figures 3M–R). The cell morphological
characteristics of small-cell carcinoma was similar to that of lung
small-cell carcinoma, including delicate nuclear chromatin, little
cytoplasm, lack of obvious nucleoli, and occasional necrosis,
expression of neuroendocrine markers or not. In addition, there
were some tumors whose histological morphology was intermediate
cell type between small-cell carcinoma and prostate acinar
adenocarcinoma, with relatively more cytoplasm and occasionally
visible small nucleoli, and showed neuroendocrine differentiation,
these cases were also included in this group. We did not include
cases of Paneth cell-like differentiation.

Clinicopathological Features of Usual
CRPC and T-NEPC
T-NEPC showed a signiﬁcant association with AR and PSA
negative expression (P< 0.001) than Usual CRPC, there was no
signiﬁcant difference in Age, higher Gleason score, metastasis
and TNM stage between two groups (Table 1). In T-NEPC
patients, poorly differentiated neuroendocrine carcinoma are
more prone to AR and PSA negative expression than prostate
adenocarcinoma with neuroendocrine differentiation(P<0.001),
there was no signiﬁcant difference in clinicopathological features
between prostate adenocarcinoma with diffuse neuroendocrine
differentiation and prostate adenocarcinoma with focal
neuroendocrine differentiation except AR positive(P = 0.034)
(Table 2).

The Clinical Outcome of Usual CRPC
and T-NEPC
A total of 113 cases of usual CRPC and 82 cases of T-NEPC were
followed up. There was a signiﬁcant difference in OS between

FIGURE 3 | The histomorphology and immunohistochemistry of prostate highly differentiated neuroendocrine cancer and poorly differentiated neuroendocrine
carcinoma. (A) Highly differentiated neuroendocrine cancer, the tumor cells show androgen receptor (AR) (B) and prostate-speciﬁc antigen (PSA) (C) negative, and
diffuse express CD56 (D), Syn (E), and CgA (F); (G) Prostate large-cell neuroendocrine carcinoma, the tumor cells show AR (H) positive, and negative express PSA
(I), diffuse express CD56 (J), Syn (K), and CgA (L); (M) Prostate small-cell carcinoma, the tumor cells show AR (N) and PSA (O) negative, and diffuse express CD56
(P), Syn (Q) and CgA (R).
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TABLE 1 | Comparison of clinicopathologic ﬁndings of Usual CRPC Versus T-NEPC.
Characteristics
Age (y)
<65
≥65
Gleason score
≤7
>7
Metastasis
No
Yes
AR
Negative
Positive
PSA
Negative
Positive
TNM stage
Stage I–II
Stage III–IV

Usual CRPC (N = 137)

T-NEPC (N = 94)

P-value

42 (30.7%)
95 (69.3%)

25 (26.6%)
69 (73.4%)

0.556

33(24.1%)
104(75.9%)

11 (19.3%)
46 (80.7%)

0.573

62 (45.3%)
75 (54.7%)

37 (39.4%)
57(60.6%)

0.418

12 (8.8%)
125 (91.2%)

29 (30.9%)
65 (69.1%)

0.000

24 (17.5%)
113 (82.5%)

45 (47.9%)
49 (52.1%)

0.000

47(34.3%)
90(65.7%)

29(30.9%)
65(69.1%)

0.312

months) lacked prognostic signiﬁcance compare with patients
with focal NE differentiation (median OS 22.9 months, 95% CI:
18.1–27.7 months, log-rank P = 0.136) (Figure 4D). But prostate
adenocarcinoma with diffuse neuroendocrine differentiation
(median OS 18.8 months, 95% CI: 15.4–22.1 months) showed
a statistically worse prognosis compare with usual CRPC
(median OS 23.6 months,95% CI: 21.3–25.9 months, log-rank
P = 0.027) (Figure 4E), while focal differentiation (median OS
22.9 months, 95% CI: 18.1–27.7 months) lacked prognostic
signiﬁcance compare with usual CRPC (median OS 23.6
months,95% CI: 21.3–25.9 months, log-rank P = 0.456)
(Figure 4F). In unadjusted Cox regressions, an excess risk of
overall death was observed in tumors with negative PSA (HR =
2.86; 95% CI = 1.39–6.73) and tumors with small-cell carcinoma
(HR = 4.35; 95% CI = 1.76–7.36) (Table 3). However, AR
negative, radiotherapy/chemotherapy, NE marker score and
present of adenocarcinoma did not show an association with
overall mortality.

Gleason score of T-NEPC only evaluate the cases of prostate adenocarcinoma with
neuroendocrine differentiation.
Bold values denote statistical signiﬁcance at the p < 0.05 level.

Clinical Characteristics and Prognostic
Factors of NEPC in the SEER Cohort
Table 4 showed the characteristics of 476 NEPC cases, including
355 pure NEPC cases and 121 cases of prostate adenocarcinoma
with NE differentiation. Compared total NEPC, pure NEPC were
more likely to have PSA <2.5 ng/ml (29.86% vs 24.37%, Table 4).
In multivariable-adjusted Cox models, an excess risk of overall
death was observed in patients aged 65 years and older (HR =
1.35, 95% CI = 1.08–1.69), patients with PSA value ≤ 2.5 ng/ml
(HR = 1.90, 95%CI=1.44–2.52), patients with PSA value 2.6–4.0
ng/ml (HR = 2.03, 95% CI = 1.38–2.99), tumor stage IV (HR =
2.13, 95% CI = 1.47–3.08) and other races than white and black
(HR = 1.85, 95% CI = 1.17–2.94) in pure NEPC after adjustment
for age at diagnosis, race, tumor stage, surgery treatment, and
PSA levels, however no statistical signiﬁcant was observed in
those who diagnosed with prostate adenocarcinoma with NE
differentiation (Table 5).

CRPC(OS from CRPC diagnosis, median OS 23.6 months,95%
CI: 21.3–25.9 months) and T-NEPC(OS from T-NEPC
diagnosis, median OS 17.6 months,95% CI: 15.3–19.9 months,
log-rank P = 0.001) (Figure 4A). The median OS of T-NEPC
patients without metastasis (median OS 21.4 months, 95% CI:
16.6–26.2 months) was signiﬁcantly higher than that of patients
with metastasis (median OS 15.7 months, 95% CI: 13.3–18.0
months, log-rank P = 0.021) (Figure 4B). In addition, we
performed a comparison between T-NEPC subgroups. TNEPC with small cell carcinoma component (median OS 9.7
months, 95% CI: 8.2–11.2 months) has a worse prognosis than
without small cell carcinoma component (median OS 20.4
months, 95% CI: 17.6–23.3 months, log-rank P = 0.000)
(Figure 4C). Prostate adenocarcinoma with diffuse NE
differentiation (median, OS 18.8 months, 95% CI: 15.3–22.3

TABLE 2 | Comparison of clinicopathologic ﬁndings of T-NEPC.
Parameter
Age (y)
<65
≥65
Metastasis
Negative
Positive
AR positivity
Negative
Positive
PSA positivity
Negative
Positive
TNM stage
Stage I–II
Stage III–IV

Pca-Focal NE (N = 23)

Pca-Diffuse NE (N = 34)

P-value

Pca-NE (N = 57)

NEC (N = 37)

P-value

6 (26.1%)
17 (73.9%)

8 (23.5%)
26 (76.5%)

0.559

16 (28.1%)
41 (71.9%)

9 (24.3%)
28 (75.7%)

0.812

10 (43.5%)
13 (56.5%)

12 (35.3%)
22 (64.7%)

0.587

22 (38.6%)
35 (61.4%)

15 (40.5%)
22 (59.5%)

1.000

0 (0%)
23 (100%)

7 (20.6%)
27 (79.4%)

0.034

7 (12.3%)
50 (87.7%)

22 (59.5%)
15 (40.5%)

0.000

6 (26.1%)
17 (73.9%)

11 (32.4%)
23 (67.6%)

0.770

17 (29.8%)
40 (70.2%)

28 (75.7%)
9 (24.3%)

0.000

9 (39.1%)
14 (60.9%)

13 (38.2%)
21(61.8%)

1.000

22 (38.6%)
35 (61.4%)

7 (18.9%)
30 (81.1%)

0.067

Pca, prostate adenocarcinoma; NE, neuroendocrine differentiation; NEC, neuroendocrine cancer
Bold values denote statistical signiﬁcance at the p < 0.05 level.
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B

D

C

E

F

FIGURE 4 | Overall survival (OS) from diagnosis of castration-resistant prostate cancer (CRPC) and treatment-emergent neuroendocrine prostate cancer (TNEPC) in a cohort of patients with CRPC and T-NEPC. (A) OS in CRPC versus T-NEPC; (B) OS in T-NEPC patients with metastasis versus without
metastasis; (C) OS in T-NEPC patients with small cell carcinoma component versus without small cell carcinoma component; (D) OS in patients with focal NE
differentiation versus diffuse NE differentiation; (E) OS in patients with diffuse NE differentiation versus usual CRPC; (F) OS in patients with focal NE
differentiation versus usual CRPC.

TABLE 3 | Univariate Cox regression analysis for overall survival in NEPC
patients with a single molecular alteration as predictor of interest.
Characteristics

Hazard ratio (95% CI)

P value

0.85[0.59–1.73]
2.86[1.39–6.73]
0.79[0.68–1.24]
1.64[0.81–3.16]
4.35[1.76–7.36]
1.05[0.46–2.33]

0.325
0.019
0.098
0.069
0.001
0.798

AR Negative
PSA Negative
NE marker score
Radiotherapy/Chemotherapy
Present of small-cell carcinoma
Present of adenocarcinoma

signaling inhibitors could promote the transformation of
adenocarcinoma in the CRPC state to T-NEPC in a clonal
manner (7, 8). Some other research found that molecular
events of T-NEPC such as TMPRSS2-ERG gene rearrangement
and fusion genes were similar to prostate adenocarcinoma,
suggested that T-NEPC originated from prostate
adenocarcinoma and ADT enabled adenocarcinoma cells to
develop into T-NEPC cells through the mechanism of adaptive
response/tumor resistance (9, 10).
Currently, 2016 WHO classiﬁcation of Tumours of the
Urinary System and Male Genital Organs divided prostate
cancers with neuroendocrine differentiation (11): usual
adenocarcinoma with neuroendocrine differentiation,
adenocarcinoma with Paneth cell-like neuroendocrine
differentiation, carcinoid tumor, small-cell neuroendocrine
carcinoma, and large-cell neuroendocrine carcinoma. Small-cell
neuroendocrine carcinoma and large-cell neuroendocrine
carcinoma are both poor-differentiated neuroendocrine
carcinomas. What’s more, there was no signiﬁcant difference in

Bold values denote statistical signiﬁcance at the p < 0.05 level.

DISCUSSION
The mechanism of T-NEPC was not clear. One explanation was
that neuroendocrine tumor cells were resistant to hormonal
therapies that target AR signaling. Therefore, ADT could
inhibit the proliferation of ordinary prostate adenocarcinoma
cells and relieved clinical symptoms of patients, while preserving
and enriching neuroendocrine tumor cells. The use of potent AR
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TABLE 4 | Comparison of participant characteristics by histological subtype among 476 neuroendocrine prostate cancer from Surveillance, Epidemiology, and End
Results (SEER) 18 registries, 2004–2017.
Characteristics

Age at diagnosis, mean, years
Age at diagnosis, years
<65
≥65
Year of diagnosis
2004–2010
2011–2017
Race
White
Black
Others
Tumor TNM stage
Stage II
Stage III
Stage IV
Unknown
Surgery, yes
PSA level
≤ 2.5 ng/ml
2.6–4.0 ng/ml
4.1–10.0 ng/ml
10.1–20.0 ng/ml
> 20.0 ng/ml
Survival time, mean, months

Total NEPC (n=476)

Pure NEPC (n=355)

NE differentiation (n=121)

N (%) orMean (SE)a

N (%) orMean (SE)a

N (%) orMean (SE)a

68.28 (0.47)

68.31 (0.56)

68.20 (0.88)

167 (35.08)
309 (64.92)

125 (35.21)
230 (64.79)

42 (34.71)
79 (65.29)

185 (38.87)
291 (61.13)

145 (40.85)
210 (59.15)

40 (33.06)
81 (66.94)

401 (84.24)
46 (9.66)
29 (6.09)

297 (83.66)
35 (9.86)
23 (6.48)

104 (85.95)
11 (9.09)
6 (4.96)

52 (10.92)
16 (3.36)
390 (81.93)
18 (3.78)
131 (27.52)

40 (11.27)
10 (2.82)
289 (81.41)
16 (4.51)
93 (26.20)

12 (9.92)
6 (4.96)
101 (83.47)
2 (1.65)
38 (31.40)

116 (24.37)
41 (8.61)
109 (22.90)
51 (10.71)
159 (33.40)
20.04 (1.22)

106 (29.86)
33 (9.30)
80 (22.54)
40 (11.27)
96 (27.04)
17.73 (1.34)

10 (8.26)
8 (6.61)
29 (23.97)
11 (9.09)
63 (52.07)
26.81 (2.68)

PSA, prostatic speciﬁc antigen; SE, Standard error; SEER, Surveillance, Epidemiology, and End Results.
a
Presented as N and % (column percentage) or Mean and SE (standard error).

TABLE 5 | Multivariablea hazard ratios for overall mortality among 476 neuroendocrine prostate cancer from SEER 18 registries, 2004–2017.
Parameter

PSA level
≤ 2.5 ng/ml
2.6–4.0 ng/ml
4.1–10.0 ng/ml
10.1–20.0 ng/ml
> 20.0 ng/ml
Age at diagnosis, years
<65
≥65
Race
White
Black
Others
Tumor TNM stage
Stage II
Stage III
Stage IV
Surgery
Yes
No

Total NEPC (n=476)

Pure NEPC (n=355)

Death number

HR

95% CI

P-value Death number

97
35
80
34
114

1.90
2.03
1.09
1.10
Ref

1.44–2.52
1.38–2.99
0.81–1.47
0.74–1.62
–

<.001
<.001
0.57
0.65
–

119
241

Ref
–
1.35 1.08–1.69

306
33
21

NE differentiation (n=121)

HR

95% CI

P-value Death number

HR

95% CI

P-value

89
28
63
31
72

1.67
1.83
1.10
1.32
Ref

1.21–2.31
1.17–2.86
0.77–1.57
0.86–2.04
–

0.002
0.008
0.60
0.21
–

8
7
17
3
42

1.54 0.69–3.42
2.30 0.97–5.45
0.828 0.45–1.53
–
–
Ref
–

0.29
0.06
0.55
–
–

–
0.008

96
187

Ref
–
1.35 1.05–1.74

–
0.02

23
54

Ref
–
1.204 0.72–2.01

–
0.48

Ref
–
1.17 0.81–1.69
1.85 1.17–2.94

–
0.40
0.009

239
26
18

Ref
–
1.04 0.68–1.58
2.17 1.30–3.62

–
0.02
0.003

67
7
3

Ref
–
1.447 0.63–3.32
1.493 0.43–5.18

–
0.38
0.53

33
5
309

Ref
–
–
–
2.13 1.47–3.08

–
–
<.001

25
4
241

Ref
–
–
–
2.52 1.64–3.86

–
–
<.001

8
1
68

Ref
–
–
–
1.174 0.54–2.58

–
–
0.69

103
256

1.17 0.92–1.48
Ref
–

0.20
–

78
204

1.24 0.94–1.63
Ref
–

0.13
–

25
52

1.196 0.71–2.02
Ref
–

0.50
–

a
Multivariable models were adjusted for age at diagnosis, race, tumor stage, surgery treatment, and PSA levels.
Bold values denote statistical signiﬁcance at the p < 0.05 level.

treatment between them, and there were some overlaps in
morphology in some cases. In addition, prostate
adenocarcinoma with diffuse neuroendocrine differentiation
Gleason score 5 + 5 = 10 (grade group 5) showed overlapping

Frontiers in Oncology | www.frontiersin.org

features of large-cell carcinoma due to its morphological crossing
(12). The prognosis of adenocarcinoma with Paneth cell-like
neuroendocrine differentiation was completely different from
that of T-NEPC, which may be just a morphological change

7

February 2021 | Volume 10 | Article 571308

Zhang et al.

Treatment-Emergent Neuroendocrine Prostate Cancer

small-cell carcinoma, we believed that it should be diagnosed as
T-NEPC even if all the neuroendocrine indicators were
negative. T-NEPC, especially small-cell carcinoma, tended to
have AR and PSA negative, however, in adenocarcinoma with
neuroendocrine differentiation, AR was often positive and PSA
expression was weakened or negative. Recent studies on TNEPC had shown that AR often positively expressed in tumor
cells, but despite the AR protein expression in the nucleus, the
transcriptional activity of AR was very low, which indicated
that epigenetic mechanisms may inhibit AR function (16). Our
study found that the negative PSA expression was an
independent prognostic factor, these results were consistent
with previous reports (17, 18). As T-NEPC and primary
neuroendocrine prostate cancer showed similar molecular
pathological characteristics (1), we validated our results
using the SEER NEPC database. Our results showed that in
pure NEPC, the prognosis of patients with low serum PSA level
(≤4 ng/ml) were signiﬁcantly worse than other PSA (>4 ng/
ml) groups.
In summary, T-NEPC had highly invasive, rapid progress,
and poor prognosis, and was related to resistance to ADT.
Although the effect of chemotherapy was not very satisfactory,
the progress of molecular diagnostic testing was expected to
create favorable conditions for the development of precision
medicine (19). Pathologists and clinicians should pay attention
to the timely diagnosis and treatment of T-NEPC to improve the
survival time of patients.

and should not be classiﬁed as T-NEPC. Therefore, we
recommended classiﬁcation T-NEPC as adenocarcinoma with
n e u r o e n d o c r i n e d i ff e r e n t i a t i o n , w e l l - d i ff e r e n t i a t e d
ne uroe ndocrine carcino ma a nd po or-diff erentiate d
neuroendocrine carcinoma.
The 2019 WHO classiﬁcation of digestive system tumors
divided the neuroendocrine neoplasm (NEN) into two
categories according to mitotic count and the Ki-67 index of
hotspots: highly differentiated neuroendocrine tumor (NET) and
poorly differentiated neuroendocrine caicinoma (NEC). NET
includes NET G1, G2, and G3, which still retained high
differential morphological features of NEN, and NEC included
large-cell and small-cell carcinoma (13). However, compared
with the tumors of the digestive system, the mitotic count and ki67 index of prostate cancer were generally low, so it could not be
classiﬁed according to the classiﬁcation standard of
gastrointestinal neuroendocrine tumors. Some study has found
that Ki-67 was an independent prognostic predictor of prostate
cancer. However, due to a low number of cases, the cut-off value
to deﬁne a proliferation index of different grades of prostate
neuroendocrine carcinoma was not established, and further
studies were needed.
When prostate cancer patients were clinically resistant to
hormonal therapy, presented with the clinical features such as
carcinoid syndrome, lower urinary tract symptoms, osteolytic
bone metastases, visceral metastases as progressive metastases
on imaging (14). In addition, an increase of serum
neuroendocrine markers CGA and NSE, or the low level or
signiﬁcantly elevated level of PSA was disproportionate to
tumor progression, the possibility of T-NEPC should be
considered (15). And it was recommended to re-biopsy the
rapidly progressing lesion to exclude the diagnosis of T-NEPC.
Urologists and pathologists should strengthen strategic
communication, and pathologists should be reminded to
perform immunohistochemical analysis of neuroendocrine
markers. Due to the classic prostate adenocarcinoma can also
showed different degrees of neuroendocrine differentiation, and
scattered or clustered neoplastic neuroendocrine cells could
appear in prostate cancer. So immunohistochemistry for
neuroendocrine markers were not recommended for general
use on prostate acinar adenocarcinoma. Therefore, the
diagnostic rate of T-NEPC was also hovering at a low level.
We suggested that for CRPC patients with repeated biopsy and
metastatic Gleason score 5 + 5 = 10 after the failure of
endocrine therapy, routine neuroendocrine markers (Syn,
CgA, and CD56) examination should be performed to
exclude the diagnosis of T-NEPC. Our results showed that
f o c a l n e u r o e n d o c r i n e d i ff e r e n t i a t i o n o f p r o s t a t e
adenocarcinoma was not a prognostic factor. Due to the
possibility of non-speciﬁc staining, in the absence of the
typical histomorphological manifestations of T-NEPC, we
suggested that T-NEPC pathological diagnosis should follow
strict deﬁnition and combine with the use of multiple
neuroendocrine markers and morphological features: at least
1 neuroendocrine marker with a diffuse (>50%) positive could
be diagnosed. However, if the morphological features of typical

Frontiers in Oncology | www.frontiersin.org
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